300355-23-1Relevant articles and documents
Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients
Sarabu, Ramakanth,Bizzarro, Fred T.,Corbett, Wendy L.,Dvorozniak, Mark T.,Geng, Wanping,Grippo, Joseph F.,Haynes, Nancy-Ellen,Hutchings, Stanley,Garofalo, Lisa,Guertin, Kevin R.,Hilliard, Darryl W.,Kabat, Marek,Kester, Robert F.,Ka, Wang,Liang, Zhenmin,Mahaney, Paige E.,Marcus, Linda,Matschinsky, Franz M.,Moore, David,Racha, Jagdish,Radinov, Roumen,Ren, Yi,Qi, Lida,Pignatello, Michael,Spence, Cheryl L.,Steele, Thomas,Tengi, John,Grimsby, Joseph
supporting information, p. 7021 - 7036 (2012/11/07)
Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.
Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
-
Page 13 - 14, (2010/11/30)
This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydro
Heteroaromatic glucokinase activators
-
, (2008/06/13)
2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.